[go: up one dir, main page]

MX2016006270A - Composiciones que comprenden células perfundidas de placenta humana, subpoblaciones de las mismas y sus usos. - Google Patents

Composiciones que comprenden células perfundidas de placenta humana, subpoblaciones de las mismas y sus usos.

Info

Publication number
MX2016006270A
MX2016006270A MX2016006270A MX2016006270A MX2016006270A MX 2016006270 A MX2016006270 A MX 2016006270A MX 2016006270 A MX2016006270 A MX 2016006270A MX 2016006270 A MX2016006270 A MX 2016006270A MX 2016006270 A MX2016006270 A MX 2016006270A
Authority
MX
Mexico
Prior art keywords
compositions
cells
human placental
placental perfusate
subpopulations
Prior art date
Application number
MX2016006270A
Other languages
English (en)
Inventor
P Gurney Jodi
Zhang Xiaokui
Herb Stacy
J Hariri Robert
Original Assignee
Anthrogenesis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthrogenesis Corp filed Critical Anthrogenesis Corp
Publication of MX2016006270A publication Critical patent/MX2016006270A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan en la presente composiciones que comprenden células mononucleares a partir de perfusión placentaria y métodos para utilizar tales células, incluyendo utilizar las células junto con células hematopoyéticas, por ejemplo, para establecer quimerismo, reducir la severidad o duración de una enfermedad de injerto contra huésped, tratar o mejorar los síntomas de sarcopenia, trastornos metabólicos y trastornos hematológicos, tales como neoplasias hematológicas, y tratar o mejorar los síntomas de encefalopatía isquémica (por ejemplo, encefalopatía isquémica hipóxica) y otras lesiones del sistema nervioso central.
MX2016006270A 2013-11-15 2014-11-14 Composiciones que comprenden células perfundidas de placenta humana, subpoblaciones de las mismas y sus usos. MX2016006270A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361905077P 2013-11-15 2013-11-15
US201361905076P 2013-11-15 2013-11-15
PCT/US2014/065665 WO2015073800A2 (en) 2013-11-15 2014-11-14 Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses

Publications (1)

Publication Number Publication Date
MX2016006270A true MX2016006270A (es) 2016-09-07

Family

ID=53058264

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016006270A MX2016006270A (es) 2013-11-15 2014-11-14 Composiciones que comprenden células perfundidas de placenta humana, subpoblaciones de las mismas y sus usos.
MX2021003799A MX2021003799A (es) 2013-11-15 2016-05-13 Composiciones que comprenden celulas perfundidas de placenta humana, subpoblaciones de las mismas y sus usos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021003799A MX2021003799A (es) 2013-11-15 2016-05-13 Composiciones que comprenden celulas perfundidas de placenta humana, subpoblaciones de las mismas y sus usos.

Country Status (11)

Country Link
US (2) US20160279171A1 (es)
EP (1) EP3068432A4 (es)
JP (4) JP2016537362A (es)
KR (3) KR20240023709A (es)
CN (2) CN105916521A (es)
AU (3) AU2014348454A1 (es)
CA (1) CA2930573C (es)
MX (2) MX2016006270A (es)
RU (1) RU2016123361A (es)
WO (1) WO2015073800A2 (es)
ZA (1) ZA201603270B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707491B2 (en) * 2016-11-11 2023-07-25 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods of treating neurodegenerative disorders
AU2018234827B2 (en) 2017-03-15 2024-04-04 Orca Biosystems Inc. Compositions and methods for hematopoietic stem cell transplants
KR20210111244A (ko) * 2018-11-30 2021-09-10 셀룰래리티 인코포레이티드 태반-유래 동종이계 car-t 세포 및 이의 용도

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10001172A1 (de) 2000-01-13 2001-07-26 Max Planck Gesellschaft Templatieren von Feststoffpartikeln mit Polymermultischichten
US20080152629A1 (en) * 2000-12-06 2008-06-26 James Edinger Placental stem cell populations
US20030032179A1 (en) 2000-12-06 2003-02-13 Hariri Robert J. Post-partum mammalian placenta, its use and placental stem cells therefrom
EP2206772A3 (en) 2000-12-06 2010-08-04 Robert J. Hariri Method of collecting placental stem cells
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
WO2002063962A1 (en) * 2001-02-14 2002-08-22 Hariri Robert J Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
US7700090B2 (en) 2002-02-13 2010-04-20 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US20080063652A1 (en) * 2004-03-29 2008-03-13 Cytomatrix, Llc Methods for Production of Regulatory T Cells and Uses Thereof
AU2006304277B2 (en) * 2005-10-13 2012-07-05 Celularity Inc. Immunomodulation using placental stem cells
KR101900809B1 (ko) * 2005-12-29 2018-09-20 안트로제네시스 코포레이션 태반 줄기 세포 집단
ES2420957T3 (es) * 2006-01-23 2013-08-28 Athersys, Inc. Tratamiento con MAPC de lesiones y enfermedades cerebrales
CN101483998A (zh) * 2006-05-11 2009-07-15 武部直子 收集和使用胎盘脐血干细胞的方法
EP3483263A1 (en) * 2006-10-23 2019-05-15 Celularity, Inc. Methods and compositions for treatment of bone defects with placental cell populations
CA2677679A1 (en) * 2007-02-12 2008-08-21 Anthrogenesis Corporation Hepatocytes and chondrocytes from adherent placental stem cells; and cd34+, cd45- placental stem cell-enriched cell populations
EP2164953A4 (en) * 2007-06-18 2010-06-30 Childrens Hosp & Res Ct Oak METHOD OF ISOLATING STAIN AND PRECIPITATING CELLS FROM PLAZENTA
KR101644659B1 (ko) * 2007-09-26 2016-08-01 안트로제네시스 코포레이션 인간 태반 관류액으로부터의 혈관형성 세포
KR20230065354A (ko) * 2007-09-28 2023-05-11 셀룰래리티 인코포레이티드 인간 태반 관류액 및 인간 태반-유래 중간체 천연 킬러 세포를 사용한 종양 억제 방법
MX2011005230A (es) * 2008-11-21 2011-06-16 Anthrogenesis Corp Tratamiento de enfermedades, desordenes o condiciones del pulmon usando celulas de placenta.
EP2405912A2 (en) * 2009-03-12 2012-01-18 University Of South Florida Method of disease-induced and receptor-mediated stem cell neuroprotection
US20100323446A1 (en) * 2009-06-05 2010-12-23 Jill Renee Barnett Method of collecting placental cells
WO2011008277A2 (en) * 2009-07-14 2011-01-20 Massachusetts Institute Of Technology Hematopoietic stromal progenitor cells and uses thereof
US20110280849A1 (en) * 2010-03-26 2011-11-17 Anthrogenesis Corporation Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
TW202011974A (zh) 2010-04-07 2020-04-01 美商安瑟吉納西斯公司 利用胎盤幹細胞之血管新生
AU2011279201B2 (en) * 2010-07-13 2016-01-21 Celularity Inc. Methods of generating natural killer cells
JP2014507389A (ja) * 2010-12-17 2014-03-27 アントフロゲネシス コーポレーション 羊膜由来接着細胞を使用する脊髄損傷及び外傷性脳損傷の治療
KR20130128438A (ko) 2010-12-17 2013-11-26 안트로제네시스 코포레이션 양막 유래 부착성 세포를 사용한, 면역-관련 질환 및 장애의 치료
AR084753A1 (es) 2010-12-30 2013-06-05 Anthrogenesis Corp Composiciones que comprenden celulas adherentes derivadas del saco amniotico (amdac) y plasma rico en plaquetas (prp)
WO2013055476A1 (en) * 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
RU2015108761A (ru) * 2012-08-13 2016-10-10 Антродженезис Корпорейшн Природные клетки-киллеры и их применение
DK2909314T3 (da) * 2012-10-19 2021-03-08 Celularity Inc Behandling af smerte med amnion afledte vedhæftende celler

Also Published As

Publication number Publication date
CA2930573A1 (en) 2015-05-21
CN105916521A (zh) 2016-08-31
JP2016537362A (ja) 2016-12-01
JP2024016037A (ja) 2024-02-06
KR20240023709A (ko) 2024-02-22
CN113679740A (zh) 2021-11-23
JP2020019777A (ja) 2020-02-06
CA2930573C (en) 2023-12-05
JP2022020622A (ja) 2022-02-01
AU2020202182A1 (en) 2020-04-16
US20160279171A1 (en) 2016-09-29
ZA201603270B (en) 2022-09-28
AU2022215291A9 (en) 2022-11-24
KR20210121277A (ko) 2021-10-07
WO2015073800A2 (en) 2015-05-21
EP3068432A2 (en) 2016-09-21
RU2016123361A (ru) 2017-12-20
WO2015073800A3 (en) 2015-07-02
AU2014348454A1 (en) 2016-06-02
EP3068432A4 (en) 2017-04-19
WO2015073800A8 (en) 2015-12-17
US20190117705A1 (en) 2019-04-25
AU2022215291A1 (en) 2022-09-01
KR20160098244A (ko) 2016-08-18
MX2021003799A (es) 2021-06-04

Similar Documents

Publication Publication Date Title
MX2023001226A (es) Anticuerpos anti-lag-3.
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
MX2018015656A (es) Compuestos heterociclicos como antibacterianos.
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
MX2016005556A (es) Compuestos agonistas duales de gip-glp-1 y procedimientos.
PH12015502767A1 (en) Sc-� cells and compositions and methods for generating the same
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
EA201890201A1 (ru) Антибактериальные соединения
MX354955B (es) Benzimidazoles y benzopirazoles sustituidos como antagonistas de ccr(4).
PH12016501457B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
NZ709215A (en) Compositions comprising anti-cd38 antibodies and lenalidomide
BR112017006664A2 (pt) terapias de combinação
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
MX2018015657A (es) Compuestos heterociclico como antibacterianos.
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
ECSP14000606A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
PH12018500379A1 (en) Biopharmaceutical compositions
MX356163B (es) Anilinas sustituidas como antagonistas de ccr(4).
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
PH12017501028A1 (en) Treatment of retinal degeneration using progenitor cells
NZ741785A (en) 3-cyano-1h-1,2,4-triazol-1-yl compounds and uses thereof for the treatment of hiv
WO2016048861A3 (en) Heterocyclic compounds and use thereof
CL2016000939A1 (es) Compuestos derivados de pirimidina con actividad inhibidora de syk uso en el tratamiento de una condición inmune, enfermedades inflamatorias, trastornos alérgicos, lupus eritomatosos, epoc, bronquitis, rinitis alérgica, asma, entre otras composición farmacéutica que los comprende.